USFDA Approves Shionogi's Xocova for Post-Exposure Prevention of Symptomatic COVID-19
Written By : sheeba farhat
Published On 2026-06-02 13:41 GMT | Update On 2026-06-02 13:41 GMT
Advertisement
Tokyo: Japan's Shionogi & Co said on Monday the U.S. Food and Drug Administration (USFDA) has approved its oral antiviral Ensitrelvir, commercially known as Xocova, for the preventive treatment of individuals who have been exposed to COVID-19.
"XOCOVA is the first and only oral option clinically proven to help prevent symptomatic COVID-19 after exposure among study participants regardless of vaccination status," Nathan McCutcheon, CEO of Shionogi's U.S. unit, said in a statement.
The financial impact of the FDA approval of Xocova in the current fiscal year ending March 2027 has already been reflected in the earnings forecast announced last month, Shionogi said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.